AstraZeneca Pharma India share news, announcements and annual reports
NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap
AstraZeneca Pharma India Limited · Formerly Astra IDL · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1982 on BSE, May 2001 on NSE
Last close ₹6,364.50up ₹65.50 (1.04%)BSE ₹6,367.35
Share price at the NSE close on 30 Oct 2026. Previous close ₹6,299.00.
30 Oct: open ₹6,300.00, high ₹6,380.00, low ₹6,240.50
52-week range of traded prices to 30 Oct 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,911 Cr333rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 93.81
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 18.23
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.57%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 24.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,84556.8% delivered
AstraZeneca Pharma India share news and announcements
671 announcements, routine notices left out, newest first. Page 10 of 14.
Jul 2017
Jun 2017
29 Jun · Legal
Exchange has sought clarification from AstraZeneca Pharma India Limited with respect to announcement dated 29-Jun-2017, regarding appointment of Mr. Gagan Singh Bedi as Additional Director on the Board.On basis of above you are required to clarify following -1. Disclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.
May 2017
9 May · Results
Apr 2017
Feb 2017
3 Feb · Legal
Exchange has sought clarification from AstraZeneca Pharma India Limited with respect to announcement dated 03-Feb-2017, regarding "AstraZeneca Pharma India Limited has informed the Exchange regarding outcome of meeting of the Board of Directors of the Company held on February 02, 2017.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.2 Feb · Results
Jan 2017
Dec 2016
Nov 2016
15 Nov · Change in Company Secretary/Compliance Officer
11 Nov · Results
Oct 2016
4 Oct · Legal
Exchange has sought clarification from the Company with respect to recent news item captioned Embassy buys 10 acre land in Bengaluru for Rs. 255 cr .In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing regulations. The response from the Company is awaited.
Aug 2016
12 Aug · Regulation 44(3) of SEBI (LODR), Reg., 2015
Jul 2016
Jun 2016
16 Jun · Statement on Impact of Audit Qualifications
May 2016
Apr 2016
Mar 2016
Feb 2016
Jan 2016
Dec 2015
3 Dec · Board meeting
Nov 2015
Oct 2015
Sep 2015